Drug Approval | January 31, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The product will be manufactured at Lupin’s Nagpur facility in India
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
